• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

耐药性卵巢癌细胞的生物学行为及CIK干预后CA125和HE4水平的变化。

The biological behavior of drug-resistantovarian cancer cells and changes in the CA125 and HE4 levels after CIK interventions.

作者信息

Chen Chenchen, Lv Yanhua

机构信息

Department of Gynecology, Affiliated Hospital of Jining Medical University Jining 272000, Shandong Province, China.

出版信息

Am J Transl Res. 2021 Apr 15;13(4):2976-2982. eCollection 2021.

PMID:34017464
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8129276/
Abstract

OBJECTIVE

This study aimed to investigate the biological behavior of drug-resistant ovarian cancer cells and changes in the cancer antigen 125 (CA125) and human epididymal protein 4 (HE4) levels after the application of cytokine-induced killer (CIK) intervention.

METHODS

Drug-resistant ovarian cancer cells (namely SKVCR) were treated with CIK at different concentrations to observe the changes in the cell survival and cell morphology and the CA125, HE4, cytokine transforming growth factor-α (TGF-α), and tumor necrosis factor-α (TNF-α) levels in the cell lines before and after intervention.

RESULTS

With an increase in the CIK concentration, the survival rate of the SKVCR cell lines showed a decreasing trend. Under a constant CIK concentration, the survival rate of the SKVCR cell lines gradually decreased over time but become stable at 72 h. Before the CIK intervention, the SKVCR cells were full and rounded in shape, but after the CIK intervention, there was remarkable cell shrinkage and an increase in apoptotic cells. Compared with before the CIK intervention, the CA125 and HE4 levels were significantly decreased, but the TGF-α and TNF-α levels were increased (<0.05).

CONCLUSION

After the CIK intervention in the drug-resistant ovarian cancer cells, the cell survival rate decreases with an increase in the CIK concentration or an extension of the intervention time, and the cell morphology will be significantly improved, and the CA125, HE4, and other related cytokine levels will also change significantly, suggesting that CIK can kill drug-resistant ovarian cancer cells.

摘要

目的

本研究旨在探讨耐药卵巢癌细胞的生物学行为以及细胞因子诱导的杀伤细胞(CIK)干预后癌抗原125(CA125)和人附睾蛋白4(HE4)水平的变化。

方法

用不同浓度的CIK处理耐药卵巢癌细胞(即SKVCR),观察细胞存活和细胞形态的变化以及干预前后细胞系中CA125、HE4、细胞因子转化生长因子-α(TGF-α)和肿瘤坏死因子-α(TNF-α)水平。

结果

随着CIK浓度的增加,SKVCR细胞系的存活率呈下降趋势。在CIK浓度恒定的情况下,SKVCR细胞系的存活率随时间逐渐降低,但在72小时时趋于稳定。CIK干预前,SKVCR细胞饱满且呈圆形,但CIK干预后,细胞明显皱缩,凋亡细胞增加。与CIK干预前相比,CA125和HE4水平显著降低,但TGF-α和TNF-α水平升高(<0.05)。

结论

CIK干预耐药卵巢癌细胞后,细胞存活率随CIK浓度增加或干预时间延长而降低,细胞形态将得到显著改善,CA125、HE4等相关细胞因子水平也会发生显著变化,提示CIK可杀伤耐药卵巢癌细胞。

相似文献

1
The biological behavior of drug-resistantovarian cancer cells and changes in the CA125 and HE4 levels after CIK interventions.耐药性卵巢癌细胞的生物学行为及CIK干预后CA125和HE4水平的变化。
Am J Transl Res. 2021 Apr 15;13(4):2976-2982. eCollection 2021.
2
The utility of human epididymal protein 4, cancer antigen 125, and risk for malignancy algorithm in ovarian cancer and endometriosis.人附睾蛋白 4、癌抗原 125 及恶性肿瘤风险算法在卵巢癌和子宫内膜异位症中的应用。
Int J Gynecol Cancer. 2012 Feb;22(2):238-44. doi: 10.1097/IGC.0b013e318234f852.
3
Comparison of ovarian cancer markers in endometriosis favours HE4 over CA125.子宫内膜异位症中卵巢癌标志物的比较显示,人附睾蛋白4优于癌抗原125。
Mol Med Rep. 2015 Oct;12(4):5179-84. doi: 10.3892/mmr.2015.4062. Epub 2015 Jul 8.
4
The value of 18F-FDG PET/CT imaging combined with detection of CA125 and HE4 in the diagnosis of recurrence and metastasis of ovarian cancer.18F-FDG PET/CT 显像联合 CA125 和 HE4 检测在卵巢癌复发转移诊断中的价值。
Eur Rev Med Pharmacol Sci. 2020 Jul;24(13):7276-7283. doi: 10.26355/eurrev_202007_21882.
5
Comparison of CA125, HE4, and ROMA index for ovarian cancer diagnosis.CA125、HE4 和 ROMA 指数在卵巢癌诊断中的比较。
Curr Probl Cancer. 2019 Apr;43(2):135-144. doi: 10.1016/j.currproblcancer.2018.06.001. Epub 2018 Jun 12.
6
Research on application value of combined detection of serum CA125, HE4 and TK1 in the diagnosis of ovarian cancer.血清 CA125、HE4 和 TK1 联合检测在卵巢癌诊断中的应用价值研究。
Eur Rev Med Pharmacol Sci. 2017 Oct;21(20):4536-4541.
7
Serum HE4 as a useful biomarker in discriminating ovarian cancer from benign pelvic disease.血清 HE4 作为一种有用的生物标志物,可用于区分卵巢癌与良性盆腔疾病。
Int J Gynecol Cancer. 2012 Jul;22(6):1000-5. doi: 10.1097/IGC.0b013e318249bee7.
8
[Comparison of serum cancer antigen 125, human epididymis protein 4, ROMA, and CPH-I for diagnosis of ovarian cancer in Chinese patients with ovarian mass].血清癌抗原125、人附睾蛋白4、ROMA及CPH-I在中国卵巢肿物患者中诊断卵巢癌的比较
Nan Fang Yi Ke Da Xue Xue Bao. 2019 Dec 30;39(12):1393-1401. doi: 10.12122/j.issn.1673-4254.2019.12.02.
9
Evaluation of HE4 as an extrabiomarker to CA125 to improve detection of ovarian carcinoma: is it time for a step forward?评估 HE4 作为 CA125 的额外生物标志物以提高卵巢癌的检测:是否是向前迈进的一步?
Arch Gynecol Obstet. 2013 Jul;288(1):167-72. doi: 10.1007/s00404-013-2722-2. Epub 2013 Jan 30.
10
Diagnostic performance and establishment of reference limits of HE4 in Korean healthy women.韩国健康女性中HE4的诊断性能及参考限值的确定
Gynecol Oncol. 2016 Oct;143(1):128-134. doi: 10.1016/j.ygyno.2016.07.100. Epub 2016 Jul 15.

本文引用的文献

1
FABP4 as a key determinant of metastatic potential of ovarian cancer.FABP4 作为卵巢癌转移潜能的关键决定因素。
Nat Commun. 2018 Jul 26;9(1):2923. doi: 10.1038/s41467-018-04987-y.
2
NIR-II nanoprobes in-vivo assembly to improve image-guided surgery for metastatic ovarian cancer.近红外二区纳米探针对转移性卵巢癌的术中引导成像的改善作用。
Nat Commun. 2018 Jul 24;9(1):2898. doi: 10.1038/s41467-018-05113-8.
3
Centromere protein U facilitates metastasis of ovarian cancer cells by targeting high mobility group box 2 expression.着丝粒蛋白U通过靶向高迁移率族蛋白盒2的表达促进卵巢癌细胞转移。
Am J Cancer Res. 2018 May 1;8(5):835-851. eCollection 2018.
4
Expression of glycolytic enzymes in ovarian cancers and evaluation of the glycolytic pathway as a strategy for ovarian cancer treatment.糖酵解酶在卵巢癌中的表达及糖酵解途径作为卵巢癌治疗策略的评估。
BMC Cancer. 2018 Jun 5;18(1):636. doi: 10.1186/s12885-018-4521-4.
5
Role of tumor microenvironment in ovarian cancer pathobiology.肿瘤微环境在卵巢癌病理生物学中的作用。
Oncotarget. 2018 Apr 27;9(32):22832-22849. doi: 10.18632/oncotarget.25126.
6
New Therapies for Ovarian Cancer.卵巢癌的新疗法。
J Natl Compr Canc Netw. 2018 May;16(5S):632-635. doi: 10.6004/jnccn.2018.0034.
7
Histone Methyltransferase EZH2: A Therapeutic Target for Ovarian Cancer.组蛋白甲基转移酶 EZH2:卵巢癌的治疗靶点。
Mol Cancer Ther. 2018 Mar;17(3):591-602. doi: 10.1158/1535-7163.MCT-17-0437.
8
Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer.个体化癌症疫苗能有效调动卵巢癌抗肿瘤 T 细胞免疫。
Sci Transl Med. 2018 Apr 11;10(436). doi: 10.1126/scitranslmed.aao5931.
9
USP15-dependent lysosomal pathway controls p53-R175H turnover in ovarian cancer cells.USP15 依赖性溶酶体途径控制卵巢癌细胞中 p53-R175H 的降解。
Nat Commun. 2018 Mar 28;9(1):1270. doi: 10.1038/s41467-018-03599-w.
10
The RNA binding protein SORBS2 suppresses metastatic colonization of ovarian cancer by stabilizing tumor-suppressive immunomodulatory transcripts.RNA 结合蛋白 SORBS2 通过稳定肿瘤抑制性免疫调节转录本抑制卵巢癌的转移性定植。
Genome Biol. 2018 Mar 16;19(1):35. doi: 10.1186/s13059-018-1412-6.